12/17/2024 Update on Atopic Dermatitis

Robert Sidbury, MD, MPH Professor, Dermatology Department of Pediatrics University of Washington PRESENTATION OBJECTIVES: 1. Highlight newly described co-morbidities 2. Discuss new topical therapies 3. Review newly FDA approved systemic agents and promising pipeline drugs DISCLOSURES: Robert Sidbury, MD, MPH, has the following financial relationships: • Investigator: Sanofi-Regeneron (Dupilumab) • Consultant: Lilly (Lebrikizumab); Leo (Tralokinumab) • Co-chair: American Academy of Dermatology AD Guidelines of Care Committee